

BC CANCER FUNDING ALGORITHM FOR METASTATIC COLORECTAL CANCER.
Last Revised 1 Dec 2022

RAS and *BRAF* wildtype + unsuitable for Bevacizumab
Chemotherapy* +/- Panitumumab †

Chemotherapy*†
(+ Bevacizumab if now suitable for Bevacizumab)

RAS and *BRAF* wildtype + no prior Panitumumab
- Panitumumab, or
- Cetuximab + irinotecan

MMR Proficient

RAS or *BRAF* mutant
Chemotherapy* +/- Bevacizumab

Chemotherapy*†
(+/- bevacizumab)

BRAF V600E mutation
Encorafenib + Panitumumab

Chemotherapy*†
(+ Bevacizumab if not already used)

dMMR/MSI-High

Pembrolizumab

BRAF V600E mutation
Encorafenib + Panitumumab

Chemotherapy* +/- Bevacizumab

Chemotherapy*†
(+ Bevacizumab if not already used)

RAS and *BRAF* wildtype + unsuitable for Bevacizumab
Chemotherapy* +/- Panitumumab †

Chemotherapy*†
(+ Bevacizumab if now suitable for Bevacizumab)

RAS and *BRAF* wildtype + no prior Panitumumab
- Panitumumab, or
- Cetuximab+ irinotecan

RAS mutant
Chemotherapy* +/- Bevacizumab

Chemotherapy*†
(+ Bevacizumab if not already used)

Other systemic therapy at the discretion of clinician

*Fluorouracil (or capecitabine) + Irinotecan, or + Oxaliplatin
†Agents not used in 1st line chemotherapy
‡ Patients with newly identified *BRAF* mutation at a later point are still eligible for encorafenib + panitumumab